Answers are grounded in this paper and cite their sources.
Systematic review demonstrates the viability of 64Cu-trastuzumab PET/CT for identifying HER2-positive metastatic breast cancer, highlighting implications for treatment decisions.
Purpose: [64Cu]Cu-NOTA/DOTA-trastuzumab PET/CT imaging can non-invasively identify human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). In addition to presenting literature-based evidence for dosimetry and pharmacologic safety of [64Cu]Cu- NOTA/DOTA-trastuzumab in patients, this systematic review aims to demonstrate the viability of [64Cu]Cu-trastuzumab PET/CT in identifying and assessing trastuzumab tumor uptake in people with HER2-positive metastatic BC. Methods: We searched the PubMed, Scopus, and EMBASE databases to find pertinent English-language papers concerning [64Cu]Cu- NOTA/DOTA-trastuzumab PET/CT for BC diagnosis. Other items were also manually searched. Conclusion: The feasibility of [64Cu]Cu -trastuzumab PET/CT for the identification of HER2-positive lesions was reviewed. [64Cu]Cu-DOTA/NOTA-trastuzumab reveals HER2-positive metastatic BC with high sensitivity and is effective in surveying distributed disease. Moreover, [64Cu] Cu-labeled trastuzumab may possibly be applied to decide on the right patients and right timing for HER2 therapy, to observe the treatment response after HER2-targeted therapy, and not only for the detection of primary HER2-positive BC but also for metastatic HER2-positive lesions. The advancement of [64Cu]Cu-trastuzumab PET/CT for the detection of BC is encouraging. However, more studies are required to determine the usefulness rate of imaging plans for clinical administrations.
No takes yet. Share an insight, caveat, or question.
Kadhim et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: